Overall | No PMRT | Received PMRT | ||
Characteristic | N or Mean (%) | N or Mean (%) | N or Mean (%) | p-value |
Total patients | 72 | 55 | 17 | -- |
Age at mastectomy | 60 | 54 | 48 | 0.03 |
Type of cancer | ||||
DCIS | 8 (11.1) | 8 (14.5) | 0 (0) | 0.25 |
Ductal | 56 (77.8) | 41 (74.6) | 15 (88.2) | |
Lobular | 8 (11.1) | 6 (10.9) | 2 (11.8) | |
Invasive tumor size | ||||
0 - 1 cm | 14 (19.4) | 12 (21.8) | 2 (11.8) | 0.23 |
1 - 2 cm | 28 (38.9) | 20 (36.4) | 8 (47.1) | |
2 - 5 cm | 22 (30.1) | 15 (27.3) | 7 (41.2) | |
Histologic Grade | ||||
0 | 9 (12.5) | 9 (16.4) | 0 (0) | 0.321 |
1 | 12 (16.7) | 8 (14.6) | 4 (23.5) | |
2 | 31 (43.1) | 23 (41.8) | 8 (47.1) | |
3 | 20 (27.8) | 15 (27.3) | 5 (29.4) | |
Lymphovascular invasion (LVI) | 0.031 | |||
Absent | 60 (83.3) | 49 (89.1) | 11 (64.7) | |
Present | 12 (16.7) | 6 (10.9) | 6 (35.3) | |
Estrogen receptor status | 0.08 | |||
Negative | 21 (29.2) | 12 (23.6) | 8 (47.1) | |
Positive | 51 (70.8) | 42(76.4) | 9 (52.9) | |
Underwent chemotherapy | 0.041 | |||
No | 57 (79.2) | 47 (85.5) | 10 (58.9) | |
Yes | 15 (20.8) | 8 (14.55) | 7 (41.2) | |
Received endocrine therapy | 0.02 | |||
No | 51 (70.8) | 35 (63.6) | 16 (94.1) | |
Yes | 21 (29.2) | 20 (36.4) | 1 (5.9) | |
Recurrence | 7 (9.7) | 7 (12.7) | 0 (0) | 0.19 |
Local | 4(5.6) | 4(7.3) | 0 (0) | 0.57 |
Distal | 3 (4.2) | 3 (5.5) | 0 (0) | 0.99 |